HOME >> BIOLOGY >> NEWS
New European legislation impacts on both cancer trials and drug approval

New European legislation impacts on both cancer trials and drug approvalParis, France, Wednesday 2 November 2005 - New European legislation looks set to expedite patient access to important oncology products, according to discussions at the 13th European Cancer Conference (ECCO). Yet concerns were also voiced that the recently implemented Clinical Trials Directive is having a converse effect, restricting the number of new cancer trials carried out by impinging on the conduct of international, investigator-initiated, multicentre studies within Europe.

The aims of the Clinical Trials Directive are noble to harmonise legal acts for the set-up, conduct and reporting of clinical trials, implement GCP-principles Europe-wide and enforce patient safety. Yet there are concerns that its mandatory implementation will be to the detriment of future non-commercial trials as requirements, obligations and clinical costs associated with the new legislation continue to increase. In order to investigate differences, obstacles and pitfalls for the conduct of future multicentre trials in member states, a comparative European analysis was undertaken.

Evidence from this examination of 8 member states whose legislation has been adapted in line with the new requirements highlights major differences in the scope of the revised legislations, as well as differences in sponsorship and liability issues. The findings described at ECCO reveal that only a few member states have expressively added provisions for non-commercial trials into their legislation for example, by specifying the use of commercially available products or allowing for exemption from IRB/dossier approval fees. Furthermore, no common definitions exist throughout the EU for 'Phase IV' studies, nor the term 'investigator-initiated' or 'non-interventional studies.'

The conclusion is that the new legal framework for clinical trials renders the realisation of future pan-European multi-centre studies much mo
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
2-Nov-2005


Page: 1 2 3

Related biology news :

1. European Science Foundations Forward Look reaches out beyond the endless frontiers
2. The UAB heads a European research project on proteases and pathological processes
3. Journalists can register now for ECCO 14 -- the European Cancer Conference
4. Climate changes brews trouble for marine life in European Seas, Marine Board-ESF report says
5. Early Europeans unable to stomach milk
6. European launch of International Polar Year 2007-2008
7. IDIBAPS participates in European Network on antibiotic resistances and hospital infections
8. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
9. European launch of International Polar Year 2007-2008
10. European Federation of Biotechnology and Elsevier announce launch of biotechnology journal
11. Putting a face on the earliest modern Europeans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/18/2019)... (PRWEB) , ... December 17, 2019 , ... ... the pharmaceutical, biotech, medical device, and diagnostics industries, has named Pharmafusion LLC as ... an impressive year for the company and its founder/CEO Jonathan Retano. Earlier in ...
(Date:12/14/2019)... ... December 10, 2019 , ... ... probiotic yeasts derived from food are able to reduce the virulence of, and ... infections in hospitalized and immune-compromised individuals, including the multi-drug resistant Candida auris, which ...
(Date:12/14/2019)... (PRWEB) , ... December 12, 2019 , ... ... products that protect or enhance crop yields, has appointed Jean Pougnier as chief ... and establish relationships with go-to-market partners and influencers that will position the company ...
Breaking Biology News(10 mins):
(Date:1/10/2020)... ... January 09, 2020 , ... A ... establishes benchmarks for the vendor qualification process, a critical element of clinical trial ... and complexity of the vendor qualification process creates delays in initiation in 7% ...
(Date:1/10/2020)... ... January 09, 2020 , ... GenScript Biotech Corp., one of ... Forum on Jan. 14 in San Francisco, coinciding with the JP Morgan Healthcare ... Booming China Market," will feature gene and cell therapy leaders in industry, academia ...
(Date:1/8/2020)... ... January 08, 2020 , ... RMA of ... and individuals grow their family, has announced that five of their Board-Certified reproductive ... Since 1991, the renowned publishing company Castle Connolly has compiled the ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... Vuja De ... cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM ... and CEO of Vuja De said, “We are delighted to welcome Chand and Lee ...
Breaking Biology Technology:
Cached News: